Safety and Efficacy Evaluation of S (+) - Ketamine in Children
Launched by CHINESE PLA GENERAL HOSPITAL · Apr 3, 2021
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Children often suffer acute pain,awakening delirium, anxiety and depression after operation which may affect the recovery of children. S (+) - ketamine has been described to decrease acute pain and opioid consumption,but it needs to confirm for chinese children undergoing surgery.
Objective:
To evaluate the analgesic effect of perioperative administration of S (+) - ketamine on postoperative acute pain in children undergoing surgery, and explore the effects of S (+) - ketamine on postoperative awakening delirium, postoperative anxiety and depression mood ,as well find the best usage, incl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≤17 years;
- • 2. Scheduled for elective digestive tract surgery, orthopedic surgery, urological surgery , ear surgery or other surgeries under general anesthesia;
- • 3. ASA physical status I~Ⅲ;
- • 4. The informed consent form was signed by the patients or the guardians.
- Exclusion Criteria:
- • 1. The expected length of hospital stay of the patient is less than 48h;
- • 2. Patients expected to be admitted to the ICU after surgery;
- • 3. Patients expected to return to the ward with tracheal catheter after surgery;
- • 4. Be allergic to S (+) - ketamine;
- • 5. Patients with severe disorder of consciousness or mental system diseases (schizophrenia, mania, bipolar disorder, psychosis, etc.) or cognitive dysfunction;
- • 6. Patients with congenital heart disease or severely developmental retardation;
- 7. Patients with any of the following contraindications of S (+) - ketamine:
- • 1. Patients with risk of serious rise of blood pressure or intracranial pressure;
- • 2. Patients with high intraocular pressure (glaucoma) or penetrating ocular trauma;
- • 3. Patients with poorly controlled or untreated hypertension (Resting systolic blood pressure greater than 180 mmHg, or resting diastolic blood pressure greater than 100mmHg);
- • 4. Patients with untreated or undertreated hyperthyroidism.
About Chinese Pla General Hospital
The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Weidong Mi, MD
Study Chair
Chinese PLA General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials